December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

117.24 +0.64 (+0.55%)
Delayed Quote Updated: 12:17 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
News headline image
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
News headline image
How This Pharma Company Can Benefit From Its Competitors ↗
Delays in FDA approval for Incyte could spell good news for Sanofi. 
Via The Motley Fool
News headline image
3 Promising Oncology Stocks To Consider Adding To Your Portfolio ↗
With tech integration and DNA sequencing increasing the efficacy of potential cancer drugs in the pipeline, we believe biotech names AstraZeneca, Amgen and Incyte are worth adding to a portfolio. 
Via Talk Markets
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (RAD) Virtual Conference
From Incyte
Via Business Wire
News headline image
Incyte Announces U.S. FDA Has Extended the New Drug Application Review Period for Ruxolitinib Cream for the Treatment of Atopic Dermatitis
From Incyte Corporation
Via Business Wire
News headline image
Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)
From Incyte
Via Business Wire
News headline image
MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a... 
From MorphoSys AG
Via AccessWire
News headline image
Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL
From Incyte
Via Business Wire
News headline image
Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial ↗
Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of... 
Via Benzinga
News headline image
Constellation Pharma Rockets On Word Of $1.7 Billion MorphoSys Takeover ↗
MorphoSys announced its $1.7 billion plan to acquire cancer treatment biotech Constellation on Wednesday and CNST stock rocketed to a four-month high. 
Via Investor's Business Daily
News headline image
BriaCell Stock Doubles After Reporting Overall Survival Benefit in Pretreated Breast Cancer Patients ↗
BriaCell Therapeutics Corp (NASDAQ: BCTX) has provided an update on the overall survival (OS) data on its previously disclosed heavily pretreated advanced breast... 
Via Benzinga
News headline image
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates ↗
The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive... 
Via Benzinga
News headline image
Week In Review: Nikang Raises $200 Million From US And China Investors ↗
NiKang Therapeutics, a clinical stage Delaware biotech, raised $200 million in a Series C financing from US and China investors. NiKang was originally incubated by CBC Group (C-Bridge Capital) in... 
Via Talk Markets
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte's Ruxolitinib Cream Aces Late-Stage Vitiligo Trials, Teeing Up Regulatory Submissions ↗
Incyte Corporation (NASDAQ: INCY) has announced positive topline results from its pivotal Phase 3 TRuE-V trial program evaluating ruxolitinib cream in... 
Via Benzinga
News headline image
Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo
From Incyte
Via Business Wire
News headline image
The QQQ Was Hammered Again Today. Here's Why. ↗
U.S. indices were trading lower across the board Wednesday after CPI data showed an increase in U.S. inflation, which has weighed on stocks. 
Via Benzinga
News headline image
Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress
From Incyte
Via Business Wire
News headline image
Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
News headline image
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
News headline image
Incyte Corp (INCY) Q1 2021 Earnings Call Transcript ↗
INCY earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Incyte's Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance ↗
Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Recap: Incyte Q1 Earnings ↗
Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 123.43% year over year to $0.67, which... 
Via Benzinga
News headline image
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies ↗
Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream... 
Via Benzinga
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.